Mar 23, 2022 / 02:30PM GMT
Paul Richard Knight - KeyBanc Capital Markets Inc., Research Division - MD & Senior Analyst
This is Paul Knight, analyst at KeyBanc. With us today, we have Paul Surdez, IR Head of Catalent. Thanks for being here, Paul; and Tom Castellano, Chief Financial Officer. We will start with Tom doing a brief overview. There will be -- is on your chat, you can enter questions or e-mail them to myself as well. But with that, Tom, I'll let you begin.
Thomas P. Castellano - Catalent, Inc. - Senior VP & CFO
Great. Thanks, Paul, and thanks, everyone, for joining. Happy to be here to represent Catalent. Just a couple of quick opening comments for me. We're coming off of another strong quarter in our second quarter here in fiscal '22, where we continue strong financial momentum.
We had 32% organic revenue growth, and 38% organic adjusted EBITDA growth during the second quarter. And that was really driven by our Biologics segment, which continues to, I would say, really carry the load from a financial perspective. We saw nearly 60% organic revenue growth in our
Catalent Inc at KeyBanc Capital Markets Life Sciences & MedTech Forum (Virtual) Transcript
Jan 22, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers